Biopharma – Page 2

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

4 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma

5 months ago talkbio0Tagged Antibody-Drug Conjugates, ArriVent, Biopharma, Lepu Biopharma, Malignant neoplasm of gastrointestinal tract, MRG007

ArriVent BioPharma, Lepu Biopharma, MRG007, Antibody Drug Conjugate (ADC), Gastrointestinal Cancers, Exclusive License Agreement

Empowering Women’s Health: First Lady Jill Biden and Biopharma Leaders Unite at JPM25

5 months ago talkbio0Tagged Biopharma, first, Health care facility, J.P. Morgan, Jill Biden, JPM25, women 's health

JPM25, Women’s Health, First Lady Jill Biden, Biopharma, Healthcare Investment, J.P. Morgan Healthcare Conference

Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges

5 months ago talkbio0Tagged 2025, Biopharma, business career, CDMO, Charles, constraints, Drug Industry, IL31RA gene, revenue outlook, River Laboratories, spending, trends qualifier

Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends

Key Takeaways from #JPM25: Strategic Partnerships and Acquisitions Dominate the JP Morgan Healthcare Conference

5 months ago talkbio0Tagged Acquisitions, Biopharma, Eli, Eli Lilly, Industry, J.P. Morgan Healthcare, JPM25, partnerships, Pharma, Scorpions, SmithKline Beecham, Zealand

JP Morgan Healthcare Conference, #JPM25, biopharma industry, acquisitions, partnerships, Eli Lilly, Zealand Pharma, GSK, Scorpion Therapeutics

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

5 months ago talkbio0Tagged Acquisition, Biopharma, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A

Celebrating Visionaries: Insights from the 2024 Fierce 50 Honorees

6 months ago talkbio0Tagged 2024, Advocacy, Biopharma, Fierce, Health Equity, healthcare innovation, honorees

Fierce 50, 2024 Honorees, Healthcare Innovation, Biopharma, Health Equity, Patient Advocacy

Biotech Industry’s Turbulent Year: Fierce Biotech’s Top 10 Most-Read Stories of 2024

6 months ago talkbio0Tagged Biopharma, biotech industry, J.P. Morgan Healthcare, M&A, rejections, shutdowns, trends qualifier, United States Food and Drug Administration

Biotech industry, layoffs, site shutdowns, FDA rejections, M&A deals, J.P. Morgan Healthcare Conference, biopharma trends

Javara Undergoes Restructuring, Lays Off Staff Amidst Industry-Wide Challenges

6 months ago talkbio0Tagged Biopharma, Clinical Research, Industry, Javara, restructuring

Javara, layoffs, restructuring, clinical research, biopharma industry challenges

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

6 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology